Company Overview - The company is Hangzhou Minsheng Health Pharmaceutical Co., Ltd., with the stock code 301507 and the abbreviation Minsheng Health [1] - The company focuses on four main product lines: liver disease, chronic diseases, ophthalmology and dermatology, and hematological oncology [1] Business Growth - The vitamin and mineral segment is expected to maintain steady growth due to the introduction of new products through both online and offline channels [1] - The company is expanding its product coverage by deepening offline channels and expanding online channels [1] New Product Launch - The new smoking cessation drug, Minsheng Lesuke (Varenicline Tartrate), is currently in the initial launch phase, with pre-sales on platforms like JD Health and Alibaba Health [2] - The drug is recommended as a first-line treatment by WHO and clinical guidelines in China and the US [2] Product Features - Minsheng Lesuke features a warm color packaging design to convey a positive message and enhance user recognition [2] - The product uses a dual aluminum high barrier packaging to ensure stability and ease of use, catering to the needs of elderly patients with a small dosage specification of 0.5mg [2] - A unique scientific smoking cessation app is provided to support users throughout their quitting journey [2] Investor Participation - The investor relations activity included participation from various financial institutions, including Dongwu Securities, Xinda Securities, and Huaxia Fund, among others [3][4]
民生健康(301507) - 投资者关系活动记录表2025-012